Skip to main content
×
×
Home

Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses

  • Tobias Rowland (a1), Benjamin I. Perry (a2), Rachel Upthegrove (a3), Nicholas Barnes (a4), Jayanta Chatterjee (a5), Daniel Gallacher (a6) and Steven Marwaha (a7)...
Abstract
Background

A reliable biomarker signature for bipolar disorder sensitive to illness phase would be of considerable clinical benefit. Among circulating blood-derived markers there has been a significant amount of research into inflammatory markers, neurotrophins and oxidative stress markers.

Aims

To synthesise and interpret existing evidence of inflammatory markers, neurotrophins and oxidative stress markers in bipolar disorder focusing on the mood phase of illness.

Method

Following PRISMA (Preferred Reporting Items for Systematic reviews and Meta-analyses) guidelines, a systematic review was conducted for studies investigating peripheral biomarkers in bipolar disorder compared with healthy controls. We searched Medline, Embase, PsycINFO, SciELO and Web of Science, and separated studies by bipolar mood phase (mania, depression and euthymia). Extracted data on each biomarker in separate mood phases were synthesised using random-effects model meta-analyses.

Results

In total, 53 studies were included, comprising 2467 cases and 2360 controls. Fourteen biomarkers were identified from meta-analyses of three or more studies. No biomarker differentiated mood phase in bipolar disorder individually. Biomarker meta-analyses suggest a combination of high-sensitivity C-reactive protein/interleukin-6, brain derived neurotrophic factor/tumour necrosis factor (TNF)-α and soluble TNF-α receptor 1 can differentiate specific mood phase in bipolar disorder. Several other biomarkers of interest were identified.

Conclusions

Combining biomarker results could differentiate individuals with bipolar disorder from healthy controls and indicate a specific mood-phase signature. Future research should seek to test these combinations of biomarkers in longitudinal studies.

Declaration of interest

None.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Correspondence: Steven Marwaha, Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK. Email: s.marwaha@warwick.ac.uk
Footnotes
Hide All
*

These authors contributed equally to the work.

Footnotes
References
Hide All
1Merikangas, KR, Jin, R, He, JP, Kessler, RC, Lee, S, Sampson, NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68: 241–51.
2Krahn, GL. WHO World Report on Disability: a review. Disabil Health J 2011; 4: 141–2.
3Saunders, KE, Bilderbeck, AC, Price, J, Goodwin, GM. Distinguishing bipolar disorder from borderline personality disorder: a study of current clinical practice. Eur Psychiatry 2015; 30: 965–74.
4Baldessarini, RJ, Tondo, L, Baethge, CJ, Lepri, B, Bratti, IM. Effects of treatment latency on response to maintenance treatment in manic-depressive disorders. Bipolar Disord 2007; 9: 386–93.
5Joyce, K, Thompson, A, Marwaha, S. Is treatment for bipolar disorder more effective earlier in illness course? A comprehensive literature review. Int J Bipolar Disord 2016; 4: 19.
6Munkholm, K, Vinberg, M, Vedel Kessing, L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013; 144: 1627.
7Fernandes, BS, Molendijk, ML, Kohler, CA, Soares, JC, Leite, CM, Machado-Vieira, R, et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med 2015; 13: 289.
8Green, EK, Raybould, R, Macgregor, S, Hyde, S, Young, AH, O'Donovan, MC, et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK. Br J Psychiatry 2006; 188: 21–5.
9Lu, B, Pang, PT, Woo, NH. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005; 6: 603–14.
10Grande, I, Fries, GR, Kunz, M, Kapczinski, F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010; 7: 243–50.
11Wu, R, Fan, J, Zhao, J, Calabrese, JR, Gao, K. The relationship between neurotrophins and bipolar disorder. Expert Rev Neurother 2014; 14: 5165.
12Lin, PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 2009; 466: 139–43.
13Polyakova, M, Stuke, K, Schuemberg, K, Mueller, K, Schoenknecht, P, Schroeter, ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2015; 174: 432–40.
14Munkholm, K, Vinberg, M, Kessing, LV. Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. Mol Psychiatry 2016; 21: 216–28.
15Fries, GR, Pfaffenseller, B, Stertz, L, Paz, AV, Dargel, AA, Kunz, M, et al. Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep 2012; 14: 667–75.
16Munkholm, K, Brauner, JV, Kessing, LV, Vinberg, M. Cytokines in bipolar disorder v. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013; 47: 1119–33.
17Modabbernia, A, Taslimi, S, Brietzke, E, Ashrafi, M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74: 1525.
18Andreazza, AC, Kauer-Sant'anna, M, Frey, BN, Bond, DJ, Kapczinski, F, Young, LT, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008; 111: 135–44.
19Brown, NC, Andreazza, AC, Young, LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 2014; 218: 61–8.
20Haenisch, F, Cooper, JD, Reif, A, Kittel-Schneider, S, Steiner, J, Leweke, FM, et al. Towards a blood-based diagnostic panel for bipolar disorder. Brain Behav Immun 2016; 52: 4957.
21Le-Niculescu, H, Kurian, SM, Yehyawi, N, Dike, C, Patel, SD, Edenberg, HJ, et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 2009; 14: 156–74.
22Dayan, CM. Interpretation of thyroid function tests. Lancet 2001; 357: 619–24.
23Haddow, JE, Palomaki, GE, Knight, GJ, Foster, DL, Neveux, LM. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. J Med Screen 1998; 5: 115–9.
24Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264–9.
25Haddaway, NR, Collins, AM, Coughlin, D, Kirk, S. The role of google scholar in evidence reviews and its applicability to grey literature searching. PLoS one 2015; 10: e0138237.
26Wells, GA, Shea, B, O'Connell, D, Peterson, JEA, Welch, V, Losos, M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute, 2000.
27Sterne, JA, Sutton, AJ, Ioannidis, JP, Terrin, N, Jones, DR, Lau, J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002.
28Lau, J, Ioannidis, JPA, Terrin, N, Schmid, CH, Olkin, I. The case of the misleading funnel plot. BMJ 2006; 333: 597600.
29Andreazza, AC, Cassini, C, Rosa, AR, Leite, MC, de Almeida, LM, Nardin, P, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatry Res 2007; 41: 523–9.
30Asdemir, A, Turan, T, Uysal, C, Kilic, E. A potential biomarker for bipolar I disorder: serum arginine vasopressin levels. Anatolian J Psychiatry 2017; 18: 195202.
31Aydemir, O, Cubukcuoglu, Z, Erdin, S, Tas, C, Onur, E, Berk, M. Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev Bras Psiquiatr 2014; 36: 293–7.
32Bai, YM, Su, TP, Tsai, SJ, Wen-Fei, C, Li, CT, Pei-Chi, T, et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord 2014; 166: 187–92.
33Barbosa, IG, Huguet, RB, Mendonca, VA, Sousa, LP, Neves, FS, Bauer, ME, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011; 261: 139–43.
34Barbosa, IG, Morato, IB, Huguet, RB, Rocha, FL, Machado-Vieira, R, Teixeira, AL. Decreased plasma neurotrophin-4/5 levels in bipolar disorder patients in mania. Rev Bras Psiquiatr 2014; 36: 340–3.
35Barbosa, IG, Rocha, NP, Huguet, RB, Ferreira, RA, Salgado, JV, Carvalho, LA, et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord 2012; 137: 151–5.
36Barbosa, IG, Rocha, NP, Miranda, AS, Huguet, RB, Bauer, ME, Reis, HJ, et al. Increased BDNF levels in long-term bipolar disorder patients. Rev Bras Psiquiatr 2013; 35: 67–9.
37Cetin, T, Guloksuz, S, Cetin, EA, Gazioglu, SB, Deniz, G, Oral, ET, et al. Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms. BMC Psychiatry 2012; 12: 158.
38Cunha, AB, Frey, BN, Andreazza, AC, Goi, JD, Rosa, AR, Goncalves, CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006; 398: 215–9.
39de Oliveira, GS, Cereser, KM, Fernandes, BS, Kauer-Sant'Anna, M, Fries, GR, Stertz, L, et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res 2009; 43: 1171–4.
40Dell'Osso, L, Bianchi, C, Del Debbio, A, Roncaglia, I, Veltri, A, Carlini, M, et al. Plasma brain-derived neurotrophic factor in bipolar and unipolar depression. Off J Italian Soc Psychopathol 2010; 16: 138–43.
41Dias, VV, Brissos, S, Frey, BN, Andreazza, AC, Cardoso, C, Kapczinski, F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord 2009; 11: 663–71.
42do Prado, CH, Rizzo, LB, Wieck, A, Lopes, RP, Teixeira, AL, Grassi-Oliveira, R, et al. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology 2013; 38: 667–76.
43Drexhage, RC, Hoogenboezem, TH, Versnel, MA, Berghout, A, Nolen, WA, Drexhage, HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immunity 2011; 25: 1206–13.
44Fernandes, BS, Gama, CS, Kauer-Sant'Anna, M, Lobato, MI, Belmonte-de-Abreu, P, Kapczinski, F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res 2009; 43: 1200–4.
45Fiedorowicz, JG, Prossin, AR, Johnson, CP, Christensen, GE, Magnotta, VA, Wemmie, JA. Peripheral inflammation during abnormal mood states in bipolar I disorder. J Affect Disord 2015; 187: 172–8.
46Gergerlioglu, HS, Savas, HA, Bulbul, F, Selek, S, Uz, E, Yumru, M. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 697702.
47Guloksuz, S, Cetin, EA, Cetin, T, Deniz, G, Oral, ET, Nutt, DJ. Cytokine levels in euthymic bipolar patients. J Affect Disord 2010; 126: 458–62.
48Hope, S, Dieset, I, Agartz, I, Steen, NE, Ueland, T, Melle, I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011; 45: 1608–16.
49Huang, TL, Lin, FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 370–2.
50Jacoby, AS, Munkholm, K, Vinberg, M, Pedersen, BK, Kessing, LV. Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder - results from a prospective study. J Affect Disord 2016; 197: 167–74.
51Kapczinski, F, Dal-Pizzol, F, Teixeira, AL, Magalhaes, PV, Kauer-Sant'Anna, M, Klamt, F, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011; 45: 156–61.
52Karamustafalioglu, N, Genc, A, Kalelioglu, T, Tasdemir, A, Umut, G, Incir, S, et al. Plasma BDNFs level initially and post treatment in acute mania: comparison between ECT and atypical antipsychotic treatment and healthy controls. J Psychopharmacol 2015; 29: 898902.
53Kenna, HA, Reynolds-May, M, Stepanenko, A, Ketter, TA, Hallmayer, J, Rasgon, NL. Blood levels of brain derived neurotrophic factor in women with bipolar disorder and healthy control women. J Affect Disord 2014; 156: 214–8.
54Kim, YK, Jung, HG, Myint, AM, Kim, H, Park, SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007; 104: 91–5.
55Kim, YK, Myint, AM, Lee, BH, Han, CS, Lee, SW, Leonard, BE, et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 2004; 129: 267–72.
56Kim, YK, Suh, IB, Kim, H, Han, CS, Lim, CS, Choi, SH, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002; 7: 1107–14.
57Legros, S, Mendlewicz, J, Wybran, J. Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. Eur Arch Psychiatry Neurol Sci 1985; 235: 911.
58Li, Z, Zhang, C, Fan, J, Yuan, C, Huang, J, Chen, J, et al. Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. Br J Psychiatry 2014; 205: 2935.
59Lin, CC, Lee, CT, Lo, YT, Huang, TL. Brain-derived neurotrophic factor protein and mRNA levels in patients with bipolar mania - a preliminary study. Biomed J 2016; 39: 272–6.
60Liu, HC, Yang, YY, Chou, YM, Chen, KP, Shen, WW, Leu, SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol 2004; 150: 116–22.
61Loch, AA, Zanetti, MV, de Sousa, RT, Chaim, TM, Serpa, MH, Gattaz, WF, et al. Elevated neurotrophin-3 and neurotrophin 4/5 levels in unmedicated bipolar depression and the effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry 2015; 56: 243–6.
62Lotrich, FE, Butters, MA, Aizenstein, H, Marron, MM, Reynolds, CF 3rd, Gildengers, AG. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry 2014; 29: 635–44.
63Machado-Vieira, R, Dietrich, MO, Leke, R, Cereser, VH, Zanatto, V, Kapczinski, F, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007; 61: 142–4.
64Mackin, P, Gallagher, P, Watson, S, Young, AH, Ferrier, IN. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry 2007; 41: 321–6.
65Munkholm, K, Pedersen, BK, Kessing, LV, Vinberg, M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology 2014; 47: 199211.
66O'Brien, SM, Scully, P, Scott, LV, Dinan, TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006; 90: 263–7.
67Ortiz-Dominguez, A, Hernandez, ME, Berlanga, C, Gutierrez-Mora, D, Moreno, J, Heinze, G, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007; 9: 596602.
68Panizzutti, B, Gubert, C, Schuh, AL, Ferrari, P, Bristot, G, Fries, GR, et al. Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: an accelerated aging biomarker? J Affect Disord 2015; 182: 64–9.
69Rabie, MA, Mohsen, M, Ibrahim, M, El-Sawy Mahmoud, R. Serum level of brain derived neurotrophic factor (BDNF) among patients with bipolar disorder. J Affect Disord 2014; 162: 6772.
70Rosa, AR, Singh, N, Whitaker, E, de Brito, M, Lewis, AM, Vieta, E, et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med 2014; 44: 2409–18.
71Selek, S, Savas, HA, Gergerlioglu, HS, Bulbul, F, Uz, E, Yumru, M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008; 107: 8994.
72Su, SC, Sun, MT, Wen, MJ, Lin, CJ, Chen, YC, Hung, YJ. Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men. Int J Psychiatry Med 2011; 42: 211–26.
73Suwalska, A, Sobieska, M, Rybakowski, JK. Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology 2010; 62: 229–34.
74Tramontina, JF, Andreazza, AC, Kauer-Sant'anna, M, Stertz, L, Goi, J, Chiarani, F, et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009; 452: 111–3.
75Tsai, SY, Chen, KP, Yang, YY, Chen, CC, Lee, JC, Singh, VK, et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry 1999; 45: 989–94.
76Tsai, SY, Chung, KH, Wu, JY, Kuo, CJ, Lee, HC, Huang, SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 2012; 136: 110–6.
77Tsai, SY, Yang, YY, Kuo, CJ, Chen, CC, Leu, SJ. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord 2001; 64: 185–93.
78Tunca, Z, Ozerdem, A, Ceylan, D, Yalcin, Y, Can, G, Resmi, H, et al. Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: the role of lithium. J Affect Disord 2014; 166: 193200.
79Uyanik, V, Tuglu, C, Gorgulu, Y, Kunduracilar, H, Uyanik, MS. Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment. Psychiatry Res 2015; 228: 386–92.
80Versace, A, Andreazza, AC, Young, LT, Fournier, JC, Almeida, JR, Stiffler, RS, et al. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol Psychiatry 2014; 19: 200–8.
81Wadee, AA, Kuschke, RH, Wood, LA, Berk, M, Ichim, L, Maes, M. Serological observations in patients suffering from acute manic episodes. Human psychopharmacology 2002; 17: 175–9.
82Yanik, M, Vural, H, Tutkun, H, Zoroglu, SS, Savas, HA, Herken, H, et al. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 2004; 254: 43–7.
83Breunis, MN, Kupka, RW, Nolen, WA, Suppes, T, Denicoff, KD, Leverich, GS, et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 2003; 53: 157–65.
84Brietzke, E, Stertz, L, Fernandes, BS, Kauer-Sant'anna, M, Mascarenhas, M, Escosteguy Vargas, A, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009; 116: 214–7.
85De Berardis, D, Conti, CM, Campanella, D, Carano, A, Scali, M, Valchera, A, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol 2008; 21: 319–24.
86Kauer-Sant'Anna, M, Kapczinski, F, Andreazza, AC, Bond, DJ, Lam, RW, Young, LT, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- v. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 447–58.
87Kunz, M, Ceresér, KM, Goi, PD, Fries, GR, Teixeira, AL, Fernandes, BS, et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 2011; 33: 268–74.
88Monteleone, P, Serritella, C, Martiadis, V, Maj, M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008; 10: 95100.
89Walz, JC, Magalhaes, PV, Giglio, LM, Cunha, AB, Stertz, L, Fries, GR, et al. Increased serum neurotrophin-4/5 levels in bipolar disorder. J Psychiatr Res 2009; 43: 721–3.
90Yatham, LN, Kapczinski, F, Andreazza, AC, Trevor Young, L, Lam, RW, Kauer-Sant'anna, M. Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. Int J Neuropsychopharmacol 2009; 12: 137–9.
91Sen, S, Duman, R, Sanacora, G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008; 64: 527–32.
92Rybakowski, JK. Response to lithium in bipolar disorder: clinical and genetic findings. ACS Chem Neurosci 2014; 5: 413–21.
93de Sousa, RT, Zarate, CA Jr, Zanetti, MV, Costa, AC, Talib, LL, Gattaz, WF, et al. Oxidative stress in early stage bipolar disorder and the association with response to lithium. J Psychiatr Res 2014; 50: 3641.
94Kato, TA, Monji, A, Mizoguchi, Y, Hashioka, S, Horikawa, H, Seki, Y, et al. Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a ‘fire extinguisher’ in the brain of schizophrenia? Mini Rev Med Chem 2011; 11: 56574.
95Cohen, J. Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates, 1988.
96Fernandes, BS, Steiner, J, Berk, M, Molendijk, ML, Gonzalez-Pinto, A, Turck, CW, et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry 2015; 20: 1108–19.
97Molendijk, ML, Spinhoven, P, Polak, M, Bus, BA, Penninx, BW, Elzinga, BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 2014; 19: 791800.
98Maes, M. A review on the acute phase response in major depression. Rev Neurosci 1993; 4: 407–16.
99Hodes, GE, Menard, C, Russo, SJ. Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress 2016; 4: 1522.
100Dowlati, Y, Herrmann, N, Swardfager, W, Liu, H, Sham, L, Reim, EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446–57.
101Haapakoski, R, Mathieu, J, Ebmeier, KP, Alenius, H, Kivimaki, M. Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immunity 2015; 49: 206–15.
102Berk, M, Kapczinski, F, Andreazza, AC, Dean, OM, Giorlando, F, Maes, M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804–17.
103Doganavsargil-Baysal, O, Cinemre, B, Aksoy, UM, Akbas, H, Metin, O, Fettahoglu, C, et al. Levels of TNF-alpha, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol 2013; 28: 160–7.
104Boll, KM, Noto, C, Bonifacio, KL, Bortolasci, CC, Gadelha, A, Bressan, RA, et al. Oxidative and nitrosative stress biomarkers in chronic schizophrenia. Psychiatry Res 2017; 253: 43–8.
105Ng, F, Berk, M, Dean, O, Bush, AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11: 851–76.
106Baek, D, Park, Y. Association between erythrocyte n-3 polyunsaturated fatty acids and biomarkers of inflammation and oxidative stress in patients with and without depression. Prostaglandins Leukot Essent Fatty Acids 2013; 89: 291–6.
107Spanemberg, L, Caldieraro, MA, Vares, EA, Wollenhaupt-Aguiar, B, Kauer-Sant'Anna, M, Kawamoto, SY, et al. Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure. Neuropsychiatr Dis Treat 2014; 10: 152331.
108Maletic, V, Raison, C. Integrated neurobiology of bipolar disorder. Front Psychiatry 2014; 5: 98.
109Haack, M, Hinze-Selch, D, Fenzel, T, Kraus, T, Kuhn, M, Schuld, A, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407–18.
110Chae, CU, Lee, RT, Rifai, N, Ridker, PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399403.
111Pischon, T, Hankinson, SE, Hotamisligil, GS, Rifai, N, Rimm, EB. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 2003; 11: 1055–64.
112Kapczinski, F, Simões Fernandes, B, Kauer-Sant'Anna, M, Gama, CS, Yatham, LN, Berk, M. The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatrica 2009; 21: 272–4.
113Sigitova, E, Fisar, Z, Hroudova, J, Cikankova, T, Raboch, J. Biological hypotheses and biomarkers of bipolar disorder. Psychiatry Clin Neurosci 2017; 71: 77103.
114McIntyre, RS, Soczynska, JK, Cha, DS, Woldeyohannes, HO, Dale, RS, Alsuwaidan, MT, et al. The prevalence and illness characteristics of DSM-5-defined ‘mixed feature specifier’ in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord 2015; 172: 259–64.
115Miller, S, Suppes, T, Mintz, J, Hellemann, G, Frye, MA, McElroy, SL, et al. Mixed depression in bipolar disorder: prevalence rate and clinical correlates during naturalistic follow-up in the Stanley Bipolar Network. Am J Psychiatry 2016; 173: 1015–23.
116Carvalho, AF, Kohler, CA, Fernandes, BS, Quevedo, J, Miskowiak, KW, Brunoni, AR, et al. Bias in emerging biomarkers for bipolar disorder. Psychol Med 2016; 46: 2287–97.
117Hayes, JF, Khandaker, GM, Anderson, J, Mackay, D, Zammit, S, Lewis, G, et al. Childhood interleukin-6, C-reactive protein and atopic disorders as risk factors for hypomanic symptoms in young adulthood: a longitudinal birth cohort study. Psychol Med 2017; 47: 2333.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Type Description Title
UNKNOWN
Supplementary materials

Rowland et al. supplementary material
Rowland et al. supplementary material 1

 Unknown (4.5 MB)
4.5 MB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses

  • Tobias Rowland (a1), Benjamin I. Perry (a2), Rachel Upthegrove (a3), Nicholas Barnes (a4), Jayanta Chatterjee (a5), Daniel Gallacher (a6) and Steven Marwaha (a7)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *